Is the performance of the international severity scoring system for familial mediterranean fever in children better than other scoring systems?

MEFV mutations children disease severity score familial mediterranean fever international severity scoring system for familial mediterranean fever

Journal

International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381

Informations de publication

Date de publication:
Nov 2021
Historique:
revised: 03 07 2021
received: 14 04 2021
accepted: 21 07 2021
pubmed: 31 7 2021
medline: 25 2 2023
entrez: 30 7 2021
Statut: ppublish

Résumé

Familial Mediterranean fever (FMF) is an autosomal recessive disorder characterised by recurrent episodes of fever and serosal inflammation with elevated acute phase reactants. Assessing the severity of the disease may be useful in identifying colchicine-resistant patients. The aim of this study is to determine the disease severity of FMF patients according to the Pras, Mor, and International Severity Scoring System for Familial Mediterranean Fever (ISSF) scoring systems and to evaluate the consistency of these three systems. The medical records of patients with FMF were retrospectively reviewed. Demographic features, family history of FMF, clinical characteristics at disease onset, laboratory features, Mediterranean fever genetic mutations, treatment regimens, and disease courses were recorded. A total of 205 patients (116 girls) were included in the study. The mean age of the patients was 13.3 ± 4.0 years. The Pras, Mor, and ISSF scores were inconsistent with each other, and there was poor fit between them (generalised Kappa: 0.140 ± 0.029; P < .001). In the receiver operating characteristic (ROC) analysis performed by accepting the clinician's opinion as the gold standard, the ISSF was found to be more sensitive and specific than the other two systems. Evaluation of disease severity according to the ISSF in paediatric patients is more sensitive and specific than the Pras and Mor scoring systems.

Identifiants

pubmed: 34328662
doi: 10.1111/ijcp.14678
doi:

Substances chimiques

Colchicine SML2Y3J35T

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14678

Informations de copyright

© 2021 John Wiley & Sons Ltd.

Références

Sohar E, Gafni J, Pras M, et al. Familial mediterranean fever, a survey of 470 cases and review of literature. Am J Med. 1967;43(2):227-253.
Bakkaloglu A. Familial mediterranean fever. Pediatr Nephrol. 2003;18(9):853-859.
Consortium FF. A candidate gene for familial mediterranean fever. Nat Genet. 1997;17:25-31.
Yıldız M, Haşlak F, Androvic A, et al. Autoinflammatory diseases in childhood. Balkan Med J. 2020;37(5):236-246. https://doi.org/10.4274/balkanmedj.galenos.2020.2020.4.82
Padeh S, Shinar Y, Pras E, et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with familial mediterranean fever. J Rheumatol. 2003;30(1):185-190.
Ozturk C, Halicioglu O, Coker I, et al. Association of clinical and genetical features in FMF with focus on MEFV strip assay sensitivity in 452 children from western Anatolia, Turkey. Clin Rheumatol. 2012;31(3):493-501.
Giancane G, Ter Haar NM, Wulffraat N, et al. Evidence-based recommmendations for genetic diagnosis of familial mediterranean fever. Ann Rheum Dis. 2015;74:635-641. https://doi.org/10.1136/annrheumdis-2014-206844
Deng Z, Sood R, Balow JE, et al. Ancient missense mutations in a new member of the roret gene family are likely to cause. Cell. 1997;90:797-807.
Tanatar A, Karadağ ŞG, Çakan M, et al. Age of onset as an influencing factor for disease severity in children with familial mediterranean fever. Mod Rheumatol. 2021;31(1):219-222.
Sönmez HE, Esmeray P, Batu ED, et al. Is age associated with disease severity and compliance to treatment in children with familial mediterranean fever? Rheumatol Int. 2019;39(1):83-87. https://doi.org/10.1007/s00296-018-4123-0
Özdel S, Özçakar ZB, Kunt SŞ, et al. Late-onset disease is associated with a mild phenotype in children with familial mediterranean fever. Clin Rheumatol. 2016;35(7):1837-1840. https://doi.org/10.1007/s10067-016-3196-y
Yalçınkaya F, Özçakar ZB, Tanyıldız M, et al. Pediatric rheumatology familial mediterranean fever in small children in Turkey. Clin Exp Rheumatol. 2011;29:87-90.
Ozkan E, Okur O, Ekmekci A, et al. A new approach to the treatment of periodic fever. Med Bull. 1972;5:44-49.
Goldfinger SE. Colchicine for familial mediterranean fever. N Engl J Med. 1972;287:1302.
Zemer D, Livneh A, Danon YL, et al. Longterm colchicine treatment in children with familial mediterranean fever. Arthritis Rheum. 1991;34(8):973-977.
Pras E, Livneh A Jr, Balow JE, et al. Clinical differences between North African and Iraqi jews with familial mediterranean fever. Am J Med Genet. 1998;75:216-219.
Mor A, Shinar Y, Zaks N, et al. Evaluation of disease severity in familial mediterranean fever. Semin Arthritis Rheum. 2005;5(6):57-64.
Kalkan G, Demirkaya E, Acikel CH, et al. Evaluation of the current disease severity scores in pediatric FMF : is it necessary to develop a new one ? Rheumatology. 2011;2012(51):743-748.
Demirkaya E, Acikel C, Hashkes P, et al. Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis. 2016;10(1136):1-6.
Yalçinkaya F, Ozen S, Ozçakar ZB, et al. A new set of criteria for the diagnosis of familial mediterranean fever in childhood. Rheumatology. 2009;48(4):395-398.
Kişla Ekıncı RM, Balci S, Akay E, et al. Disease severity and genotype affect physical growth in children with familial mediterranean fever. Arch Rheumatol. 2019;34(3):288-293.
Kişla Ekinci RM, Balci S, Ufuk Altintaş D, et al. The influence of concomitant disorders on disease severity of familial mediterranean fever in children. Arch Rheumatol. 2018;33(3):282-287.
Özdemir FMA, Gülez N, Makay B. Evaluation of the international severity score for FMF (ISSF) scores in Turkish children diagnosed with FMF: a single-center experience. Clin Rheumatol. 2021;40(8):3219-3225. https://doi.org/10.1007/s10067-021-05652-4
Jeske M, Lohse P, Kallinich T, et al. Genotype-phenotype and genotype-origin correlations in children with mediterranean fever in Germany - an AID-net study. Klin Padiatr. 2013;225:325-330.
Ozen S, Aktay N, Lainka E, et al. Disease severity in children and adolescents with familial mediterranean fever: a comparative study to explore environmental effects on a monogenic disease. Ann Rheum Dis. 2009;68(2):246-248.
Kasifoglu T, Bilge SY, Sari I, et al. Amyloidosis and its related factors in turkish patients with familial mediterranean fever: a multicentre study. Rheumatol. 2014;53(4):741-745.
Yilmaz E, Dinçel N, Sözeri B, et al. Familial mediterranean fever in children from the Aegean region of Turkey: gene mutation frequencies and phenotype-genotype correlation. Turkish J Med Sci. 2015;45(6):1198-1206.
Kosan C, Diri N, Cayir A, et al. Clinical profile of familial mediterranean fever in a pediatric population in eastern Turkey. West Indian Med J. 2016;65(2):281-286.
Giaglis S, Papadopoulos V, Kambas K, et al. MEFV alterations and population genetics analysis in a large cohort of Greek patients with familial mediterranean fever. Clin Genet. 2007;71(5):458-467.

Auteurs

Gizem Ozcan (G)

Department of Pediatric Pulmonology, Ankara University Faculty of Medicine, Ankara, Turkey.

Semsa Cayci (S)

Department of Pediatric Nephrology, Ankara City Hospital, Ankara, Turkey.

Banu Celikel Acar (B)

Department of Pediatric Rheumatology, Ankara City Hospital, Ankara, Turkey.

Ozge Basaran (O)

Department of Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Fatma Aydin (F)

Department of Pediatric Rheumatology, Ankara City Hospital, Ankara, Turkey.

Atilla Halil Elhan (AH)

Department of Biostatistics, Ankara University Faculty of Medicine, Ankara, Turkey.

Nilgun Cakar (N)

Department of Pediatric Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH